2.19
Intelligent Bio Solutions Inc stock is traded at $2.19, with a volume of 30,040.
It is down -2.23% in the last 24 hours and up +11.73% over the past month.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
See More
Previous Close:
$2.24
Open:
$2.24
24h Volume:
30,040
Relative Volume:
0.19
Market Cap:
$6.63M
Revenue:
$3.91M
Net Income/Loss:
$-11.65M
P/E Ratio:
-0.1777
EPS:
-12.3212
Net Cash Flow:
$-11.51M
1W Performance:
-4.78%
1M Performance:
+11.73%
6M Performance:
-46.52%
1Y Performance:
-87.12%
Intelligent Bio Solutions Inc Stock (INBS) Company Profile
Name
Intelligent Bio Solutions Inc
Sector
Industry
Phone
646-790-5756
Address
135 W 41ST ST,, NEW YORK
Compare INBS vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
INBS
Intelligent Bio Solutions Inc
|
2.19 | 6.63M | 3.91M | -11.65M | -11.51M | -12.32 |
|
ABT
Abbott Laboratories
|
103.36 | 178.85B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
91.62 | 117.19B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
270.01 | 103.57B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
43.10 | 62.46B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.77 | 50.01B | 6.30B | 1.07B | 1.09B | 1.8406 |
Intelligent Bio Solutions Inc Stock (INBS) Latest News
A fingerprint drug test company will discuss its FDA submission Sept. 24 - Stock Titan
Intelligent Bio Solutions submits FDA application for codeine test By Investing.com - Investing.com South Africa
Intelligent Bio Solutions Files FDA 510(k) for U.S. Market Entry - Minichart
INBS Looks 7.4% Undervalued on GF Value™ Amid Challenging Price-to-Sales Dynamics - GuruFocus
Intelligent Bio Solutions submits FDA 510(k) for fingerprint drug screen after clinical studies show >98% accuracy - TradingView
Intelligent Bio Solutions submits FDA application for codeine test - Investing.com
Intelligent Bio Solutions Submits FDA 510(k) for Drug Screening System to Detect Codeine - Quiver Quantitative
Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance - marketscreener.com
Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market - Benzinga
Intelligent Bio Solutions Raises Up to $15M in Private Placement - Minichart
Intelligent Bio Solutions Completes $5 Million Private Placement - TipRanks
Intelligent Bio Solutions Raises $5 Million in Private Placement With Warrants - TradingView
INBS|Intelligent Bio Solutions Inc|Price:2.300|Chg%:-0.170 - TradingKey
Intelligent Bio Solutions Inc. announced that it has received $4.999998 million in funding - marketscreener.com
Intelligent Bio Solutions posts >98% accuracy in multi-site study, targets Sept 2026 510(k) - TradingView
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Intelligent Bio Solutions Inc. announced that it expects to receive $4.999998 million in funding - marketscreener.com
INBS Stock Draws Traders As FDA 510(k) Milestones Pile Up - StocksToTrade
INBS Stock Steadies As FDA Milestones And Revenue Growth Stack Up - timothysykes.com
INBS Looks 3.4% Overvalued on GF Value™ - GuruFocus
Intelligent Bio Solutions reports improved drug screening accuracy By Investing.com - Investing.com India
Intelligent Bio Solutions raises $5M in private placement By Investing.com - Investing.com Canada
Intelligent Bio Solutions reports improved drug screening accuracy - Investing.com
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission - manilatimes.net
Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules - The Manila Times
A fingerprint drug test produced no false positives. Intelligent Bio Solutions expects an FDA filing in September. - Stock Titan
Press Release: Intelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq Rules - Moomoo
Intelligent Bio Solutions Inc (INBS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intelligent Bio Solutions earnings missed by $4.88, revenue fell short of estimates - Investing.com Canada
Intelligent (INBS) Range: Posts a 1.31% Loss to $2.63 in the Latest Reading; Chart View: $2.50 and $2.76 Define the Nearby Reference Levels in the Current UpdateSize Factor - vinanet.vn
Intelligent Bio Solutions completes clinical data collection for FDA 510(k) - scanx.trade
INBS Looks 0.4% Overvalued on GF Value™ - GuruFocus
Intelligent Bio Solutions Revenue Rises 38% to $4.2 Million in Fiscal 2026 - Moomoo
Intelligent Bio Solutions resolves all cybersecurity review items ahead of H2 2026 FDA filing - scanx.trade
Intelligent Bio Solutions revenue rises 38% to $4.2 million - grafa.com
BRIEF-Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth - Bitget
Form 8K Intelligent Bio Solutions Inc For: 19 August By Investing.com - Investing.com Nigeria
Intelligent Bio Solutions Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 - marketscreener.com
INBS FY26 Results: Revenue up 38% to $4.2M, margin expands to 48.6% - scanx.trade
Intelligent Bio Solutions Revenue Jumps 38% as Gross Margin Expands 778 Basis Points - Minichart
Intelligent Bio Solutions | 10-K: Annual report - Moomoo
Intelligent Bio Solutions Reports Fiscal 2026 Revenue Up 38% to $4.22M, Gross Margin 48.63% - TradingView
INBS: Revenue up 38% to $4.2M, gross margin 48.63%, FDA submission on track for late 2026 - TradingView
INTELLIGENT BIO SOLUTIONS INC. FY 2026: Revenue $4.22M, EPS $(8.44) — 10-K Summary - TradingView
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth - TradingView
Intelligent Bio (NASDAQ: INBS) warns on cash and survival - Stock Titan
Intelligent Bio Solutions grows to 502 customers as net loss widens to $12.5M - Stock Titan
Intelligent Bio Solutions Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Intelligent Bio Solutions (NASDAQ:INBS): Can Commercial Adoption Accelerate? - Kalkine Media
Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action? - TradingView
Intelligent Bio Solutions receives ISO 13485:2016 recertification - Investing.com
Intelligent Bio Solutions Inc Stock (INBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):